Lilly Delivers Strong Third-Quart...(on was completed on January 1 2006 ...),Health

January 1, 2006 (.01) (.12)

------ ------

E.P.S. (pro forma adjusted) $2.64 $2.21 19 %

------ ------

2007 Financial Guidance

The company has raised its full-year pro forma adjusted earnings guidance for 2007, and now expects full-year pro forma adjusted earnings per share to be in the range of $3.50 to $3.55 per share, representing growth of 16 to 17 percent compared with full-year 2006 pro forma adjusted results. Full-year pro forma adjusted earnings per share growth is expected to be fueled by pro forma sales growing at a faster rate than pro forma operating expenses.

For the fourth quarter, the company expects pro forma adjusted earnings per share of $0.86 to $0.91, which excludes an estimated $0.03 per share charge for acquired in-process research and development related to the MacroGenics in-licensing agreement. Including this charge, the company expects fourth-quarter reported earnings per share to be in the range of $0.83 to $0.88. The earnings per share guidance includes an anticipated increase in the effective tax rate for the fourth quarter, the impact of the potential launch of generic olanzapine by competitors in Germany, normally scheduled manufacturing shutdowns, and additional investments in research and development and sales and marketing to drive future growth.

The full-year pro forma adjusted earnings per share guidance excludes the charges noted in the tables below related to restructuring charges, acquired in-process research and development and an adjustment to insurance recoverables. Including the charges noted in the tables below, the company expects reported earnings per share to be in the range of $2.76 to $2.81 for the full year, representing growth of 13 to 15 percent compared with full-year 2006 reported results. See reco
'/>"/>